Edition:
United Kingdom

bluebird bio Inc (BLUE.OQ)

BLUE.OQ on NASDAQ Stock Exchange Global Select Market

120.02USD
16 Aug 2019
Change (% chg)

$3.03 (+2.59%)
Prev Close
$116.99
Open
$118.09
Day's High
$120.17
Day's Low
$118.09
Volume
96,487
Avg. Vol
194,113
52-wk High
$176.25
52-wk Low
$87.64

Select another date:

Fri, Jun 14 2019

Photo

Bluebird prices gene therapy at 1.58 million euros over 5 years

Bluebird bio Inc on Friday set a price for its gene therapy, Zynteglo, at 1.58 million euros ($1.78 million) over five years, after winning conditional approval in Europe this month to treat a rare genetic blood disorder.

UPDATE 1-Bluebird prices gene therapy at 1.58 mln euros over 5 years

June 14 Bluebird bio Inc on Friday set a price for its gene therapy, Zynteglo, at 1.58 million euros ($1.78 million) over five years, after winning conditional approval in Europe this month to treat a rare genetic blood disorder. The company proposed an installment plan, with 315,000 euros paid up front and four additional annual payments due only if the treatment continues to be effective.

Bluebird prices gene therapy at 1.575 mln euros over five years

June 14 Bluebird bio Inc on Friday set a price for its gene therapy, Zynteglo, at 1.575 million euros ($1.78 million) over five years, after winning conditional approval in Europe this month to treat a rare genetic blood disorder.

EMA panel recommends approval of Bluebird Bio's first gene therapy

A European Medicines Agency panel on Friday recommended a conditional marketing approval for a gene therapy from Bluebird Bio Inc as a genetic blood disorder treatment, setting the stage for the U.S. biotech to win its first regulatory nod.

UPDATE 1-EMA panel recommends approval of Bluebird Bio's first gene therapy

March 29 A European Medicines Agency panel on Friday recommended a conditional marketing approval for a gene therapy from Bluebird Bio Inc as a genetic blood disorder treatment, setting the stage for the U.S. biotech to win its first regulatory nod.

EMA panel recommends approval of Bluebird Bio's first gene therapy

March 29 A European Medicines Agency panel on Friday recommended a conditional marketing approval for a gene therapy from Bluebird Bio Inc as a genetic blood disorder treatment, setting the stage for the U.S. biotech to win its first regulatory nod.

Select another date: